Quick answer
Collective currently advertises compounded tirzepatide for $69 per month, with the medication price described as the same at any dose. A separate $199 annual membership applies after a 21-day membership trial unless canceled before the trial ends.
Collective says licensed clinicians review the intake and prescriptions are filled through licensed U.S. pharmacies. Its public pages do not identify the pharmacy that would dispense a specific patient’s prescription. The Terms also allow a separate nominal technology transaction fee for electronic prescription transmission without publishing the amount.
The product discussed on this page is compounded tirzepatide, not an FDA-approved finished drug product. FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
Affiliate disclosure: Care Path Compare may receive compensation if you use the Collective link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.
What Collective currently charges for tirzepatide
Collective’s current public pricing says:
- Medication: $69 per month for compounded tirzepatide.
- Dose pricing: Collective says the medication price stays the same at any dose.
- Membership: $199 per year after a 21-day membership trial.
- Shipping: express cold shipping is described as included.
- Care: unlimited clinician messaging, ongoing check-ins, and nutrition/lifestyle support are described as part of the membership program.
A simple 12-month illustration using 12 medication charges and one annual membership is $1,027 before any applicable technology transaction fee, taxes, or checkout-specific charges. That is an arithmetic illustration, not a guaranteed total.
Why the $69 headline needs context
The $69 figure is the advertised medication price, not a complete all-in program total.
Collective’s Terms say CollectiveOS may charge a nominal, uniform technology transaction fee for each electronic prescription transmission. The amount is not published in the Terms.
Before paying, ask for the complete charge schedule rather than relying only on the $69 headline: medication, membership, any prescription-transaction fee, laboratory charges if later required, and renewal timing.
What medication is being offered?
Collective labels this pathway compounded tirzepatide.
That regulatory category should remain clear. FDA-approved tirzepatide products have undergone FDA review for approved uses. Compounded tirzepatide is not an FDA-approved finished drug product, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
Care Path Compare does not present compounded tirzepatide as the same product as an FDA-approved branded medication or as an FDA-approved generic.
How prescribing works
Collective’s Terms require a clinician consultation and a valid prescription before a prescription product can be processed. The clinician decides whether a prescription is appropriate.
CollectiveOS says it operates the technology and membership platform rather than the medical practice. Independent clinicians remain responsible for clinical decisions.
Confirm the assigned clinician’s full name, professional designation, and active license in the state where you are physically located during the encounter. An online intake does not guarantee a prescription, a particular dose, or continued treatment.
Pharmacy transparency
Collective says its prescription products are filled through licensed U.S. pharmacies and describes third-party testing. The public pages reviewed by Care Path Compare do not name the pharmacy that would fill a specific tirzepatide prescription.
Before accepting shipment, verify:
- the pharmacy’s legal name and physical location;
- its active license for the patient’s state;
- the exact product name, formulation, concentration, and labeled directions;
- the prescriber’s identity;
- storage requirements; and
- the process for delayed, warm, damaged, or incorrect shipments.
FDA recommends that patients using compounded GLP-1 products obtain a prescription from a clinician and fill it through a state-licensed pharmacy.
Does Collective raise the tirzepatide price with dose?
Collective currently says no: the $69 medication price is advertised as the same at any dose.
That is a commercial pricing statement, not a dosing recommendation. A treating clinician should determine whether tirzepatide is appropriate and how it is prescribed or adjusted for an individual patient.
Consumers should save the checkout price and renewal terms because pricing policies can change.
What is included with membership?
Collective currently describes the $199 annual membership as covering the support surrounding the medication, including clinician messaging, ongoing check-ins, nutrition and lifestyle support, and express cold shipping.
The medication itself is billed separately at the advertised $69 monthly price.
The 21-day trial and cancellation timing
The 21-day trial applies to Collective membership. The public site says users still pay for medication during the trial.
The Terms say the membership converts automatically to the paid annual plan when the trial ends unless canceled beforehand. Paid memberships then renew annually until canceled, and membership fees are generally non-refundable with no partial-period refund except where required or expressly stated.
The date that matters most financially is therefore the trial-end date. Record it before enrolling.
Switching from another GLP-1 program
Collective publicly markets the program to people already using a GLP-1 and says a user may be able to continue a current dose if the treating clinician approves.
That should not be interpreted as a guarantee that a clinician will continue another provider’s medication, dose, formulation, or schedule. A new clinician must make an independent prescribing decision based on the patient’s current information.
If switching providers, ask what records are needed, whether a new intake or live visit is required, and what product the dispensing pharmacy would actually supply if a prescription is issued.
State availability
Collective’s public FAQ says the program is available in 44 states, but Care Path Compare has seen a conflicting partner-level state restriction list. The two sources differ on Arkansas versus Mississippi.
Because of that discrepancy, verify current eligibility for the state where you are physically located before paying rather than relying on a static state list.
Questions to ask before enrolling
- What will I be charged today and after the 21-day membership trial?
- Does the technology transaction fee apply, how much is it, and how often can it be charged?
- Which pharmacy would dispense the prescription if a clinician prescribes?
- What exact formulation and concentration would be dispensed?
- Is the program available where I am physically located?
- Could lab work or a live visit be required?
- If I am switching from another provider, what records or new evaluation are required?
- What happens financially if the clinician does not prescribe?
- What is my annual membership renewal date and cancellation deadline?
Bottom line
Collective’s tirzepatide pathway is notable for a $69 monthly advertised medication price that the company says remains the same at any dose. The program also requires a $199 annual membership, and the Terms permit an additional prescription technology fee without stating the amount.
Before enrolling, verify the complete charge schedule, current state eligibility, assigned clinician, dispensing pharmacy, exact formulation and concentration, and cancellation terms. Those details are more useful than comparing the $69 headline alone.
Affiliate disclosure: Care Path Compare may receive compensation if you use the Collective link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.
Important information
Official sources
- Collective, weight-loss program homepage, accessed October 1, 2026.
- CollectiveOS, Terms of Use, version August 12, 2026; accessed October 1, 2026.
- U.S. Food and Drug Administration, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed October 1, 2026.